Model‐based drug development in oncology is still lagging despite a good momentum in the
clinical pharmacology and pharmacometry community in the past few years. The failure rate …

Background Early radiological tumor shrinkage may be associated with better long-term
outcome in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab …

The rapid pace of discoveries in tumor biology, imaging technology, and human genetics
hold promise for an era of personalized oncology care. The successful development of a …

18 F-FDG PET and, more recently, PET/CT have been established as response biomarkers
for monitoring cytotoxic or cytoreductive cancer therapies. With the advent of targeted cancer …

BACKGROUND: In clinical trials, change in tumor size is used to stratify patients into
response categories. The objective of the current study was to: 1) determine whether early …

Purpose Early tumour shrinkage (ETS), defined as a reduction of at least 20% in tumour size
at first reassessment, has been recently investigated retrospectively in first-line trials of …

Phase II trials are screening trials that seek to identify agents with sufficient activity to
continue development and those for which further evaluation should be halted. Although …

The large number of negative phase III trials in oncology over the last several years has
renewed interest in refining phase II oncology clinical trials to maximize the chances of …

In dose‐finding clinical studies, it is common that multiple endpoints are of interest. For
instance, in phase I/II studies, efficacy and toxicity are often the primary endpoints, which are …

Summary Aim This phase I/II study of saracatinib in combination with gemcitabine in patients
with advanced pancreatic cancer was conducted by the NCIC Clinical Trials Group. The …